GERON CORP Operating Cash Flow
GERON CORP (GERN) reported Operating Cash Flow of -$78.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- GERON CORP net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$15.83M.
- GERON CORP net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$62.91M.
- GERON CORP net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$22.07M.
- GERON CORP net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$13.58M.
- GERON CORP net cash provided by (used in) operating activities for fiscal 2025 was -$111.04M.
- GERON CORP net cash provided by (used in) operating activities for fiscal 2024 was -$218.62M.
- GERON CORP net cash provided by (used in) operating activities for fiscal 2023 was -$167.74M.
- GERON CORP net cash provided by (used in) operating activities for fiscal 2022 was -$127.38M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$78.73M 10-Q · filed 2026-08-05 | -$100.80M derived: sum of 3 quarters · filed 2026-08-05 | -$114.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$62.91M 10-Q · filed 2026-05-06 | -$84.97M derived: sum of 2 quarters · filed 2026-05-06 | -$98.55M derived: sum of 3 quarters · filed 2026-05-06 | -$125.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$22.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$35.64M derived: sum of 2 quarters · filed 2026-03-02 | -$63.06M derived: sum of 3 quarters · filed 2026-08-05 | -$111.04M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$13.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$40.99M derived: sum of 2 quarters · filed 2026-08-05 | -$88.97M 10-Q · filed 2025-11-07 | -$132.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$27.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$75.39M 10-Q · filed 2026-08-05 | -$119.34M derived: sum of 3 quarters · filed 2026-08-05 | -$178.28M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$47.98M 10-Q · filed 2026-05-06 | -$91.92M derived: sum of 2 quarters · filed 2026-05-06 | -$150.87M derived: sum of 3 quarters · filed 2026-05-06 | -$204.34M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$43.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$102.89M derived: sum of 2 quarters · filed 2026-03-02 | -$156.37M derived: sum of 3 quarters · filed 2026-03-02 | -$218.62M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$58.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$112.42M derived: sum of 2 quarters · filed 2025-11-07 | -$174.67M 10-Q · filed 2025-11-07 | -$215.61M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$53.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$115.73M 10-Q · filed 2025-08-06 | -$156.67M derived: sum of 3 quarters · filed 2026-03-02 | -$207.51M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$62.25M 10-Q · filed 2025-05-07 | -$103.19M derived: sum of 2 quarters · filed 2026-03-02 | -$154.03M derived: sum of 3 quarters · filed 2026-03-02 | -$183.63M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$40.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$91.78M derived: sum of 2 quarters · filed 2026-03-02 | -$121.38M derived: sum of 3 quarters · filed 2026-03-02 | -$167.74M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$50.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$80.44M derived: sum of 2 quarters · filed 2024-11-07 | -$126.81M 10-Q · filed 2024-11-07 | -$161.99M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$29.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$75.97M 10-Q · filed 2024-08-08 | -$111.15M derived: sum of 3 quarters · filed 2025-02-27 | -$140.73M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$46.37M 10-Q · filed 2024-05-02 | -$81.55M derived: sum of 2 quarters · filed 2025-02-27 | -$111.13M derived: sum of 3 quarters · filed 2025-02-27 | -$139.77M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$35.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$64.76M derived: sum of 2 quarters · filed 2025-02-27 | -$93.41M derived: sum of 3 quarters · filed 2025-02-27 | -$127.38M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$29.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$58.22M derived: sum of 2 quarters · filed 2023-11-02 | -$92.20M 10-Q · filed 2023-11-02 | -$114.37M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$28.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$62.62M 10-Q · filed 2023-08-03 | -$84.78M derived: sum of 3 quarters · filed 2024-02-28 | -$107.62M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$33.97M 10-Q · filed 2023-05-11 | -$56.14M derived: sum of 2 quarters · filed 2024-02-28 | -$78.98M derived: sum of 3 quarters · filed 2024-02-28 | -$96.80M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$22.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$45.01M derived: sum of 2 quarters · filed 2024-02-28 | -$62.82M derived: sum of 3 quarters · filed 2024-02-28 | -$95.56M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$22.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$40.65M derived: sum of 2 quarters · filed 2022-11-07 | -$73.39M 10-Q · filed 2022-11-07 | -$86.00M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | -$17.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$50.55M 10-Q · filed 2022-08-11 | -$63.16M derived: sum of 3 quarters · filed 2023-03-16 | -$78.61M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | -$32.73M 10-Q · filed 2022-05-09 | -$45.35M derived: sum of 2 quarters · filed 2023-03-16 | -$60.80M derived: sum of 3 quarters · filed 2023-03-16 | -$73.19M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | -$12.61M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$28.06M derived: sum of 2 quarters · filed 2023-03-16 | -$40.46M derived: sum of 3 quarters · filed 2023-03-16 | -$66.65M 10-K · filed 2023-03-16 |
| 2020-09-30 | -$15.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$27.84M derived: sum of 2 quarters · filed 2021-11-09 | -$54.04M 10-Q · filed 2021-11-09 | -$64.40M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | -$12.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$38.59M 10-Q · filed 2021-08-16 | -$48.95M derived: sum of 3 quarters · filed 2022-03-10 | -$60.94M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | -$26.19M 10-Q · filed 2021-05-10 | -$36.56M derived: sum of 2 quarters · filed 2022-03-10 | -$48.54M derived: sum of 3 quarters · filed 2022-03-10 | -$57.28M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | -$10.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$22.35M derived: sum of 2 quarters · filed 2022-03-10 | -$31.09M derived: sum of 3 quarters · filed 2022-03-10 | -$43.83M 10-K · filed 2022-03-10 |
| 2019-09-30 | -$11.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$20.73M derived: sum of 2 quarters · filed 2020-11-05 | -$33.46M 10-Q · filed 2020-11-05 | -$36.47M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | -$8.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$21.48M 10-Q · filed 2020-08-06 | -$24.49M derived: sum of 3 quarters · filed 2021-03-11 | -$30.63M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | -$12.74M 10-Q · filed 2020-05-28 | -$15.75M derived: sum of 2 quarters · filed 2021-03-11 | -$21.88M derived: sum of 3 quarters · filed 2021-03-11 | -$26.38M derived: sum of 4 quarters · filed 2021-03-11 |
| 2018-12-31 | -$3.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$9.15M derived: sum of 2 quarters · filed 2021-03-11 | -$13.64M derived: sum of 3 quarters · filed 2021-03-11 | -$21.01M 10-K · filed 2021-03-11 |
| 2018-09-30 | -$6.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$10.63M derived: sum of 2 quarters · filed 2019-11-06 | -$18.00M 10-Q · filed 2019-11-06 | -$22.39M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$4.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$11.86M 10-Q · filed 2019-08-01 | -$16.25M derived: sum of 3 quarters · filed 2020-03-12 | -$20.67M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | -$7.37M 10-Q · filed 2019-05-02 | -$11.76M derived: sum of 2 quarters · filed 2020-03-12 | -$16.18M derived: sum of 3 quarters · filed 2020-03-12 | -$20.62M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | -$4.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$8.81M derived: sum of 2 quarters · filed 2020-03-12 | -$13.25M derived: sum of 3 quarters · filed 2020-03-12 | -$20.56M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$4.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$8.86M derived: sum of 2 quarters · filed 2018-11-01 | -$16.17M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | -$4.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | -$11.74M 10-Q · filed 2018-07-31 | ||
| 2017-03-31 | -$7.31M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | -$18.37M 10-K · filed 2019-03-07 | |||
| 2016-06-30 | -$11.21M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | -$24.20M 10-K · filed 2018-03-16 | |||
| 2012-06-30 | -$13.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | -$30.35M 10-Q · filed 2012-08-03 | -$51.72M derived: sum of 3 quarters · filed 2012-08-03 | -$65.99M derived: sum of 4 quarters · filed 2012-08-03 |
| 2012-03-31 | -$16.59M 10-Q · filed 2012-05-07 | -$37.95M derived: sum of 2 quarters · filed 2012-05-07 | -$52.23M derived: sum of 3 quarters · filed 2012-05-07 | -$66.27M derived: sum of 4 quarters · filed 2012-08-03 |
| 2011-12-31 | -$21.37M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-07 | -$35.64M derived: sum of 2 quarters · filed 2012-03-07 | -$49.68M derived: sum of 3 quarters · filed 2012-08-03 | -$62.39M 10-K · filed 2012-03-07 |
| 2011-09-30 | -$14.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | -$28.32M derived: sum of 2 quarters · filed 2012-08-03 | -$41.02M 10-Q · filed 2011-11-03 | -$57.18M derived: sum of 4 quarters · filed 2012-08-03 |
| 2011-06-30 | -$14.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | -$26.75M 10-Q · filed 2012-08-03 | -$42.91M derived: sum of 3 quarters · filed 2012-08-03 | -$51.87M derived: sum of 4 quarters · filed 2012-08-03 |
| 2011-03-31 | -$12.71M 10-Q · filed 2012-05-07 | -$28.86M derived: sum of 2 quarters · filed 2012-05-07 | -$37.83M derived: sum of 3 quarters · filed 2012-05-07 | |
| 2010-12-31 | -$16.16M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-07 | -$25.12M derived: sum of 2 quarters · filed 2012-03-07 | -$44.29M 10-K · filed 2012-03-07 | |
| 2010-09-30 | -$8.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | -$28.14M 10-Q · filed 2011-11-03 | ||
| 2010-06-30 | -$19.17M 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | -$43.37M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |